
Core Viewpoint - GENFIT, a biopharmaceutical company focused on rare and life-threatening liver diseases, successfully held its Combined Shareholders Meeting on June 17, 2025, where all resolutions were approved except for one [1]. Company Overview - GENFIT is dedicated to improving the lives of patients with unmet medical needs related to rare liver diseases, with over two decades of experience in liver disease research and development [3]. - The company has a diversified and expanding R&D portfolio, particularly focusing on Acute-on-Chronic Liver Failure (ACLF) with five assets under development: VS-01, G1090N, SRT-015, CLM-022, and VS-02-HE [3]. - GENFIT also targets other serious diseases, including cholangiocarcinoma (CCA), urea cycle disorder (UCD), and organic acidemia (OA) [3]. - The company has demonstrated its expertise in drug development with the accelerated approval of Iqirvo (elafibranor) for Primary Biliary Cholangitis (PBC) by major regulatory agencies [3]. - In addition to therapies, GENFIT has a diagnostic franchise focusing on metabolic dysfunction-associated steatohepatitis (MASH) and blood ammonia levels [3]. Shareholder Meeting Results - The quorum for the meeting was 27.21%, and all resolutions were approved except for resolution n°28, which was rejected based on the Board of Directors' recommendations [1]. - Detailed voting results for each resolution are available on the company's website [2].